Orszagos Onkologiai Intezet

The medical center is at the forefront of research in Non-Small Cell Lung Cancer, focusing on innovative therapies that target specific biomarkers and genetic mutations. The center's research aims to improve treatment outcomes for patients with advanced stages of NSCLC.

• PD-L1 high NSCLC
• ALK-positive NSCLC
• HER2 mutations in NSCLC

By exploring novel drug combinations and personalized medicine approaches, the center contributes significantly to the advancement of NSCLC treatment strategies.

Specializing in biochemically recurrent prostate cancer, the center conducts pivotal studies to enhance therapeutic options for patients at high risk of recurrence. The research focuses on combining androgen deprivation therapy with novel agents to improve patient outcomes.

• Androgen deprivation therapy (ADT)
• PSA marker analysis

Through these studies, the center aims to refine treatment protocols and extend progression-free survival for prostate cancer patients.

The center is a leader in the study of Renal Cell Carcinoma, focusing on immune and targeted combination therapies. Research efforts are directed towards improving safety and efficacy profiles of new treatment regimens.

• Advanced RCC therapies
• Combination treatment strategies

By evaluating novel drug combinations, the center seeks to enhance the therapeutic landscape for RCC patients.

Research at the center includes a strong focus on lymphoma, particularly follicular lymphoma and diffuse large B-cell lymphoma. The center explores innovative treatment combinations to improve patient outcomes in relapsed or refractory cases.

• Follicular Lymphoma (FL)
• Diffuse Large B-Cell Lymphoma (DLBCL)

These studies aim to develop more effective therapeutic options and improve survival rates for lymphoma patients.

The center is dedicated to advancing treatment for breast cancer, with a focus on hormone receptor-positive and HER2-negative subtypes. Research includes evaluating new drug combinations and assessing their impact on progression-free survival.

• ER+/HER2- Breast Cancer
• Metastatic Breast Cancer

Through these efforts, the center aims to provide more personalized and effective treatment options for breast cancer patients.

Focusing on endometrial cancer, the center conducts research to evaluate the efficacy of novel immunotherapy combinations. The goal is to improve progression-free survival and overall survival in patients with advanced or recurrent disease.

• Advanced Endometrial Cancer
• Recurrent Endometrial Cancer

These studies aim to enhance treatment protocols and offer new hope for endometrial cancer patients.